Previous close | 8.58 |
Open | 8.56 |
Bid | 8.72 x 100 |
Ask | 8.78 x 100 |
Day's range | 8.55 - 9.00 |
52-week range | 6.01 - 13.14 |
Volume | |
Avg. volume | 576,662 |
Market cap | 618.177M |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.72 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.96 |
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference: Zymeworks’ management will participate in one-on-one meetings on May 15th in Las
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results a